Morphic Holding stock was surging Monday after pharmaceutical giant Eli Lilly agreed to acquire the biopharmaceutical company in a $3.2 billion deal. Lilly has agreed to pay $57 a share for ...

Eli Lilly has agreed to buy biopharmaceutical company Morphic Holding for $3.2 billion in a deal that bolsters the ...

The early trial of TERN-601 is encouraging, but I wouldn't buy shares of the stock just yet. It's still far too early in the ...

Eli Lilly is selling bonds to fund the acquisition of drug developer Morphic. The sale is reportedly ... unicorn” and upgraded its shares to a buy rating. The bump was based in part on sales ...

Eli Lilly is acquisitive, too, and just purchased a company called Morphic Holding ... Eli Lilly looks like a great stock to buy and hold for the long run, while its top-notch track record ...

Eli Lilly’s Morphic acquisition brings an oral small ... Eli Lilly is paying $140 million for the exclusive right to buy Radionetics Oncology for the price of $1 billion. The clinical-stage ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 589.06% and ...

Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

The maintained Buy rating and price target signal confidence in Eli Lilly's continued growth and ... The company has also completed the acquisition of Morphic Holding (NASDAQ:MORF), Inc., adding ...

Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".